Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Zhaomei Zhang"'
Publikováno v:
Asian Journal of Surgery, Vol 47, Iss 2, Pp 1141-1142 (2024)
Externí odkaz:
https://doaj.org/article/c522d0e1d06f48209c43f7f93c33423d
Autor:
Philip Vitorino, Chen-Hua Chuang, Alexandre Iannello, Xi Zhao, Wade Anderson, Ronald Ferrando, Zhaomei Zhang, Shravanthi Madhavan, Holger Karsunky, Laura R. Saunders
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100883- (2021)
Rovalpituzumab tesirine (Rova-T) offers a targeted therapy for ~85% of SCLC patients whose tumors express DLL3, but clinical dosing is limited due to off-target toxicities. We hypothesized that a sub-efficacious dose of Rova-T combined with anti-PD1,
Externí odkaz:
https://doaj.org/article/117d11cd0102492081c6552a745ddb18
Autor:
Philip Vitorino, Alexander J. Bankovich, Monette Aujay, Zhaomei Zhang, Angeline T. Dang, Christina Lee, Dorothy French, Theodore Sullivan, Kumiko Isse, Monica You, Christine Gu, Marybeth Pysz, Hetal Sarvaiya, Xi Zhao, Alexander Schammel, Julia Gavrilyuk, Wolf R. Wiedemeyer
Supplementary Figure from ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e04dfbdd6edb05fe4f748df6a64c4e
https://doi.org/10.1158/1535-7163.22522480.v1
https://doi.org/10.1158/1535-7163.22522480.v1
Autor:
Philip Vitorino, Alexander J. Bankovich, Monette Aujay, Zhaomei Zhang, Angeline T. Dang, Christina Lee, Dorothy French, Theodore Sullivan, Kumiko Isse, Monica You, Christine Gu, Marybeth Pysz, Hetal Sarvaiya, Xi Zhao, Alexander Schammel, Julia Gavrilyuk, Wolf R. Wiedemeyer
In the past year, four antibody–drug conjugates (ADC) were approved, nearly doubling the marketed ADCs in oncology. Among other attributes, successful ADCs optimize targeting antibody, conjugation chemistry, and payload mechanism of action. Here, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::747b7f4105aad333d4f4a606f7dcdc81
https://doi.org/10.1158/1535-7163.c.6543391.v1
https://doi.org/10.1158/1535-7163.c.6543391.v1
Autor:
Hetal Sarvaiaya, Stefan Munneke, Parthasarathi Subramanian, Johannes Krieger, James W. Purcell, Kyriacos C. Nicolaou, Zhaomei Zhang, Dionisios Vourloumis, Balu D. Dherange, Julia Gavrilyuk, Monette Aujay, Christine Gu, Ganesh M. Murhade, Baiwei Lin, Joseph Sandoval
Publikováno v:
Journal of the American Chemical Society. 142:15476-15487
Taking advantage of the C2-symmetry of the antitumor naturally occurring disorazole B1 molecule, a symmetrical total synthesis was devised with a monomeric advanced intermediate as the key building...
Autor:
Wolf R. Wiedemeyer, Julia Gavrilyuk, Alexander Schammel, Xi Zhao, Hetal Sarvaiya, Marybeth Pysz, Christine Gu, Monica You, Kumiko Isse, Theodore Sullivan, Dorothy French, Christina Lee, Angeline T. Dang, Zhaomei Zhang, Monette Aujay, Alexander J. Bankovich, Philip Vitorino
Publikováno v:
Molecular cancer therapeutics. 21(6)
In the past year, four antibody–drug conjugates (ADC) were approved, nearly doubling the marketed ADCs in oncology. Among other attributes, successful ADCs optimize targeting antibody, conjugation chemistry, and payload mechanism of action. Here, w
Autor:
Shravanthi Madhavan, Wade C Anderson, Ronald Ferrando, Alexandre Iannello, Xi Zhao, Zhaomei Zhang, Holger Karsunky, Laura Saunders, Chen-Hua Chuang, Philip Vitorino
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 1, Pp 100883-(2021)
Translational Oncology, Vol 14, Iss 1, Pp 100883-(2021)
Rovalpituzumab tesirine (Rova-T) offers a targeted therapy for ~85% of SCLC patients whose tumors express DLL3, but clinical dosing is limited due to off-target toxicities. We hypothesized that a sub-efficacious dose of Rova-T combined with anti-PD1,
Autor:
K C, Nicolaou, Johannes, Krieger, Ganesh M, Murhade, Parthasarathi, Subramanian, Balu D, Dherange, Dionisios, Vourloumis, Stefan, Munneke, Baiwei, Lin, Christine, Gu, Hetal, Sarvaiaya, Joseph, Sandoval, Zhaomei, Zhang, Monette, Aujay, James W, Purcell, Julia, Gavrilyuk
Publikováno v:
Journal of the American Chemical Society. 142(36)
Taking advantage of the
Autor:
Scott J. Dylla, Zhaomei Zhang, Aaron Kempema, Sheila Bheddah, Laura Saunders, Shravanthi Madhavan, Christine Saechao, Sandro Vivona, Alina He, Marybeth Pysz, Monette Aujay, Alex Bankovich, Kimberly Walter, Erik Huntzicker, Xi Zhao, David Liu, Kristyn Hayashi, Julia Gavrilyuk, Vikram Natwarsinhji Sisodiya, Holger Karsunky, Dorothy French, Wolf R. Wiedemeyer, Johannes Hampl
Publikováno v:
Clinical Cancer Research. 25:NT-113
Disclosures: All authors are employees of AbbVie. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication. Ovarian cancer d
Autor:
Guochun Liao, Gary Peltz, Jonathan Usuka, Douglas S. Clark, Janet Cheng, Zhaomei Zhang, Paul Cheung, Erin Farrell, Paul Weller, Shao-Yong Wu, Yingying Guo, Bill Fitch, Anh Nguyen, Jianmei Wang, Steve Shafer, John Allard, Mohammad R. Masjedizadeh, Sharon Jiang
Publikováno v:
Nature Biotechnology. 24:531-536
Pharmacogenetic approaches can be instrumental for predicting individual differences in response to a therapeutic intervention. Here we used a recently developed murine haplotype-based computational method to identify a genetic factor regulating the